| Citation: |
QIAO Zhiqiang, LI Mingmei, LI Longyu. Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix[J]. Cancer Research on Prevention and Treatment, 2019, 46(8): 720-723. DOI: 10.3971/j.issn.1000-8578.2019.19.0123
|
To investigate the clinical treatment and prognostic factors of cervical small cell neuroendocrine carcinoma (SCNEC).
We selected 101 SCNEC patients in Jiangxi Maternal and Child Health Hospital and analyzed retrospectively age, clinical stage, tumor size, treatment and survival rate. All patients were divided into surgery group (stage ⅠB1-ⅡA, surgery+chemoradiotherapy, n=72) and concurrent chemoradiotherapy(CCRT) group (stage ⅡB-Ⅳ, concurrent radiotherapy and chemotherapy, n=29).
In surgery group, 51 patients survived for 1-139 months. The 5-year survival rate was 60.6%. In CCRT group, 20 patients were followed up for more than five years, with a 5-year survival rate of 15%. The survival rates of patients with different stages were significantly different (P=0.0025); those of patients with negative and positive lymph node were significantly different (P=0.0004); those of patients with pure and mixed type were not significantly different (P=0.0546).
The prognosis of patients with cervical SCNEC are closely related to the clinical stage and lymph node metastasis. The prognosis of early stage patients treated with surgery is significantly better than that of advanced stage patients treated with radical chemoradiotherapy.
| [1] |
Margolis B, Tergas AI, Chen L, et al. Natural history and outcome of neuroendocrine carcinoma of the cervix[J]. Gynecol Oncol, 2016, 141(2): 247-254. doi: 10.1016/j.ygyno.2016.02.008
|
| [2] |
Gadducci A, Carinelli S, Aletti G. Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists[J]. Gynecol Oncol, 2017, 144(3): 637-646. doi: 10.1016/j.ygyno.2016.12.003
|
| [3] |
Pei X, Xiang L, Ye S, et al. Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage Ⅰ-Ⅱ small cell neuroendocrine carcinoma of the cervix[J]. Gynecol Oncol, 2017, 147(3): 589-596. doi: 10.1016/j.ygyno.2017.09.022
|
| [4] |
Wang KL, Chang TC, Jung SM, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix:A Taiwanese Gynecologic Oncology Group study[J]. Eur J Cancer, 2012, 48(10): 1484-1494. doi: 10.1016/j.ejca.2011.12.014
|
| [5] |
Lee SW, Nam JH, Kim DY, et al. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study[J]. Int J Gynecol Cancer, 2010, 20(3): 411-416. doi: 10.1111/IGC.0b013e3181ce427b
|
| [6] |
Intaraphet S, Kasatpibal N, Siriaunkgul S, et al. Prognostic factors for small cell neuroendocrine carcinoma of the uterine cervix: an institutional experience[J]. Int J Gynecol Cancer, 2014, 24(2): 272-279. doi: 10.1097/IGC.0000000000000059
|
| [7] |
Frumovitz M, Munsell MF, Burzawa JK, et al. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix[J]. Gynecol Oncol, 2017, 144(1): 46-50. doi: 10.1016/j.ygyno.2016.10.040
|
| [8] |
Zhou J, Yang HY, Wu SG, et al. The local treatment modalities in FIGO stage Ⅰ-Ⅱ small-cell carcinoma of the cervix are determined by disease stage and lymph node status[J]. Cancer Med, 2016, 5(6): 1108-1115. doi: 10.1002/cam4.687
|
| [9] |
Ishikawa M, Kasamatsu T, Tsuda h, et al. Prognostic factors and optimal therapy for stages Ⅰ-Ⅱ neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study[J]. Gynecol Oncol, 2018, 148(1): 139-146. doi: 10.1016/j.ygyno.2017.10.027
|
| [10] |
Cohen JG, Kapp DS, Shin JY, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients[J]. Am J Obstet Gynecol, 2010, 203(4): 347. e1-e6. http://cn.bing.com/academic/profile?id=bcb56bf54b7b84c01e50b78df8dd9210&encoded=0&v=paper_preview&mkt=zh-cn
|
| [11] |
Chen TC, Huang HJ, Wang TY, et al. Primary surgery versus primary radiation therapy for FIGO stages Ⅰ-Ⅱ small cell carcinoma of the uterine cervix: A retrospective Taiwanese Gynecologic Oncology Group study[J]. Gynecol Oncol, 2015, 137(3): 468-473. doi: 10.1016/j.ygyno.2015.03.015
|
| [12] |
Li X, Yang R, Jia Y, et al. Prognostic risk factors for small cell carcinoma of the cervix and impact of platinum-based neoadjuvant chemotherapy[J]. Int J Gynaecol Obstet, 2015, 130(1): 31-35. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=83f6bfda586684438ea5195743a85196
|
| [13] |
Lee SW, Lim KT, Bae DS, et al. A multicenter study of the importance of systemic chemotherapy for patients with small-cell neuroendocrine carcinoma of the uterine cervix[J]. Gynecol Obstet Invest, 2015, 79(3): 172-178. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=9923a0aafc4ef28e57c0c7afc836da9a
|
| [14] |
Zhou J, Wu SG, Sun JY, et al. Clinicopathological features of small cell carcinoma of the uterine cervix in the surveillance, epidemiology, and end results database[J]. Oncotarget, 2017, 8(25): 40425-40433. http://cn.bing.com/academic/profile?id=deca997a709a8f24a46366f8f9fbf9bd&encoded=0&v=paper_preview&mkt=zh-cn
|
| [15] |
Satoh T, Takei Y, Treilleux I, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix[J]. Int J Gynecol Cancer, 2014, 24(9 Suppl 3): S102-S108. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=931005729089a53500140bf3ee449802
|
| [16] |
Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document[J]. Gynecol Oncol, 2011, 122(1): 190-198. doi: 10.1016/j.ygyno.2011.04.011
|
| [17] |
Kuji S, Hirashima Y, Nakayama H, et al. Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan[J]. Gynecol Oncol, 2013, 129 (3): 522-527. doi: 10.1016/j.ygyno.2013.02.025
|
| [1] | LU Hui, XIE Zhengyuan. Research Progress in Noninvasive Early Diagnosis of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 75-80. DOI: 10.3971/j.issn.1000-8578.2023.22.0642 |
| [2] | ZHU Xiaoli, XU Lu. Research Progress of Markers Related to Early Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 875-879. DOI: 10.3971/j.issn.1000-8578.2022.21.1483 |
| [3] | FENG Yangchun, XU Yi, HUANG Yanchun. Application of Cluster Analysis and Discriminant Analysis in Six Kinds of Lung Cancer Tumor Markers[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 266-269. DOI: 10.3971/j.issn.1000-8578.2015.03.012 |
| [4] | FAN Guo-yu, WU Xiao-kui, LI Chun-guo. Diagnosis Value of Tumor Markers for Malignant Pleural Effusions[J]. Cancer Research on Prevention and Treatment, 2011, 38(04): 434-436. DOI: 10.3971/j.issn.1000-8578.2011.04.018 |
| [5] | LI Wen-li, ZHAN Shu-hui, LV Mei. Re-evaluation of Multi-tumor Marker Protein Biochip Detective System in Diagnosis of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 294-297. DOI: 10.3971/j.issn.1000-8578.2011.03.014 |
| [6] | YIN Cheng-hong, WEN Yan, REN Jiang-bo, DONG Zhong, LI Jia, WAN GBao-en. Combined Different Tumor Markers in Detecting 50 Primary Hepatic Carcinoma Cases[J]. Cancer Research on Prevention and Treatment, 2005, 32(08): 502-504. DOI: 10.3971/j.issn.1000-8578.3297 |
| [7] | QU Hong-yan, PANG DA, XUE Ying-wei, et al, . Diagnosis and treatment of spleen tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(04): 316-316. DOI: 10.3971/j.issn.1000-8578.3303 |
| [8] | CAI Xiao-qing, LI Wen-guang. The diagnosis and treatment of the bladder mixed tumor[J]. Cancer Research on Prevention and Treatment, 2002, 29(02): 133-134. DOI: 10.3971/j.issn.1000-8578.941 |
| [9] | XUE Jian-ping, WANG Xian-guang, ZHU Hu, et al, . The Experimental Study of the Use of Examining SerumTumor-specific Growth Factor (TSGF) in the Preceding Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 467-468. DOI: 10.3971/j.issn.1000-8578.479 |
| [10] | LI De-ren, JI Bing-wen. The Clinical Value of Tumor Makers in the Diagnosis, Prediction Response to Chemotherapy and Prognosis in Human Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(03): 209-211. DOI: 10.3971/j.issn.1000-8578.2156 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: